Abstract 489TiP
Background
Neoadjuvant anti-programmed cell death (ligand) 1 (PD[L]-1) inhibitors + CT have shown promising efficacy improvements compared with CT alone in pts with resectable NSCLC. Exploring neoadjuvant treatment containing novel agents that retain or improve efficacy and minimize safety risks may provide more clinical options for these pts. This phase 2 study aims to evaluate the preliminary efficacy, safety, and pharmacodynamics of TIS, an anti-PD-1 monoclonal antibody (mAb), as monotherapy and in multiple immunotherapy combinations +/- CT as neoadjuvant treatment in pts with resectable NSCLC.
Trial design
This phase 2 randomized, open-label, multicenter study (14 sites) will enroll approximately 120 treatment-naïve pts aged ≥18 years with EGFR mutation and ALK-rearrangement-negative stage II to IIIA NSCLC. The umbrella design allows for multiple investigational drugs, administered alone or in combination in a single disease population. Pts will be allocated to 1 of 2 substudies based on tumor cell PD-L1 expression. Sixty pts in Substudy 1 (PD-L1 ≥50%) will be randomized 1:1:1 to TIS monotherapy (Arm 1A), TIS + ociperlimab (anti-T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains mAb) (Arm 1B), or TIS + LBL-007 (anti-LAG-3 mAb) (Arm 1C). Sixty pts in Substudy 2 (PD-L1 <50%) will be randomized 1:2 to receive histology-specific (nonsquamous vs. squamous) CT in combination with TIS (Arm 2A) or TIS + LBL-007 (Arm 2C). All treatments will be administered on a 3-week cycle for 2–4 cycles followed by surgical resection and survival follow-up. The primary endpoint is major pathological response, per blinded independent pathology review (BIPR). Secondary endpoints include pathological complete response per BIPR, overall survival, event-free survival, and disease-free survival (both per investigator; RECIST v1.1), adverse events (per CTCAE v5.0), the proportion of pts who undergo surgical resection following treatment, and pharmacodynamic assessments of the investigational agents. Enrollment is ongoing.
Clinical trial identification
NCT05577702.
Legal entity responsible for the study
BeiGene.
Funding
BeiGene.
Disclosure
W. Yu: Financial Interests, Personal, Full or part-time Employment: BeiGene, BeiGene; Financial Interests, Personal, Stocks or ownership: BeiGene, BeiGene. J. Shi: Financial Interests, Personal, Full or part-time Employment: BeiGene; Financial Interests, Personal, Stocks or ownership: BeiGene. B. Wei: Financial Interests, Personal, Full or part-time Employment: BeiGene; Financial Interests, Personal, Stocks or ownership: BeiGene. W. Zheng: Financial Interests, Personal, Full or part-time Employment: BeiGene; Financial Interests, Personal, Stocks or ownership: BeiGene. Z. Shen: Financial Interests, Personal, Full or part-time Employment: BeiGene; Financial Interests, Personal, Stocks or ownership: BeiGene. All other authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract